Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon May 27, 2024 10:57pm
155 Views
Post# 36059704

RE:Resistance to ADCs in the treatment of solid tumors

RE:Resistance to ADCs in the treatment of solid tumors May 15, 2024 - A recent ADC+ ICI combination study in TNBC presented at ESMO 2024 showed that treatment with the combination of atezolizumab (Tecentriq) plus sacituzumab govitecan-hziy (Trodelvy) led to responses in patients with locally advanced or metastatic triple-negative breast cancer (TNBC) who had a PD-L1 expression of at least 1% on immune cells (PD-L1 positive), according to data from an 18-week interim analysis of the phase 1b/2 MORPHEUS-pan BC trial (NCT03424005) "

https://www.onclive.com/view/frontline-atezolizumab-plus-sacituzumab-govitecan-elicits-responses-in-pd-l1-advanced-tnbc

[ ONCY's pelareorep has demonstrated that it's responsive to PD-L1 negative cancers. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response, that pelareorep is able to achieve through a resulting expansion of both pre-existing and new T cell clones (TiLs) in the tumor microenvironment (TME).

Results of pelareoreps's effectiveness in generating a CD8+ TiLs complex response will be presented during this week ASCO 2024 Trials in Progress poster session.

As discussed, earlier, pelareorep's ability to stimulate the immune system with consequential TiLs expansion precludes T cell exhaustion and complements both ADC and ICI therapies, with either agent, or in combination with both.]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5154949/
<< Previous
Bullboard Posts
Next >>